Abbott Reaches Preliminary Settlement in Derivative Governance Case

Abbott Laboratories ( (ABT) ) has issued an update.

Six shareholder derivative lawsuits tied to Abbott Laboratories’ U.S. infant formula business have been proceeding on a consolidated basis in federal court in Illinois, alleging that certain current and former directors and officers breached fiduciary duties and violated securities laws through inadequate oversight and misleading disclosures. On April 10, 2026, the court preliminarily approved a proposed settlement and set a June 4, 2026 hearing to consider final approval, under which Abbott would maintain or adopt governance reforms and strengthen internal reporting and compliance frameworks, changes that lead plaintiffs say will confer material benefits on the company and its shareholders while allowing Abbott and the defendants to avoid the cost and uncertainty of continued litigation.

The proposed settlement, which the defendants support while continuing to deny any wrongdoing, would see all related claims dismissed with prejudice if approved and would commit Abbott to invest in implementing the governance measures outlined in the agreement. Lead plaintiffs’ counsel, acting on a contingent-fee basis, plan to seek court-approved attorneys’ fees and expenses of up to $15.85 million, including modest service awards for the institutional lead plaintiffs, while current shareholders have been granted the right to object ahead of the June hearing, highlighting how the outcome may shape Abbott’s future compliance practices and board oversight of its infant formula operations.

The most recent analyst rating on (ABT) stock is a Buy with a $144.00 price target. To see the full list of analyst forecasts on Abbott Laboratories stock, see the ABT Stock Forecast page.

Spark’s Take on ABT Stock

According to Spark, TipRanks’ AI Analyst, ABT is a Neutral.

The score is supported by strong cash flow and a constructive earnings outlook (mid-to-high single-digit comparable sales growth, strong device performance) but held back by weak technicals (below key moving averages with negative momentum), a relatively high P/E with a modest dividend yield, and uncertainty from earnings volatility and incomplete 2025 balance sheet data.

To see Spark’s full report on ABT stock, click here.

More about Abbott Laboratories

Abbott Laboratories is a global healthcare and medical products company that manufactures and sells a wide range of diagnostics, medical devices, nutrition products such as infant formula, and branded generic medicines. The company’s infant formula operations in the United States have been a particular focus of regulatory, legal, and shareholder scrutiny in recent years.

Average Trading Volume: 12,062,511

Technical Sentiment Signal: Sell

Current Market Cap: $176.9B

For detailed information about ABT stock, go to TipRanks’ Stock Analysis page.